Clinical trial · Interventional
Effects of PG2 on Fatigue-Related Symptom Clusters
NCT02740959CI-TRIAL-00034820completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is for an "add-on" study to the "main" study (Protocol No.: PH-CP012). The information of patients from main study will be collected by questionnaire survey and actigraphy measurement to evaluate the relationship between fatigue, depression and sleep disorder and the efficacy of PG2 after treatment.The association between symptom cluster and circadian rhythm will be also further explored.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer-related Fatigue | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Astragalus Polysaccharides 250 mg | Drug | — | UNRESOLVED |
| Astragalus Polysaccharides 500 mg | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Astragalus Polysaccharides 500 mg
- description
- PG2 (500 mg in 500 ml saline), t.i.w. via i.v. infusion for 2.5-3.5 hours over 2 treatment cycles (8 weeks)
- interventionNames
- Drug: Astragalus Polysaccharides 500 mg
- type
- EXPERIMENTAL
- label
- Astragalus Polysaccharides 250 mg
- description
- PG2 (250 mg in 500 ml saline), t.i.w. via i.v. infusion for 2.5-3.5 hours over 2 treatment cycles (8 weeks)
- interventionNames
- Drug: Astragalus Polysaccharides 250 mg
Primary outcomes (3)
- measure
- Pittsburgh Sleep Quality Scale
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
Show eligibility criteria text
Inclusion Criteria: * Patients who signed the informed consent form * The age of eligible patients should be 20 years old. * Eligible patients must have locally advanced or metastatic cancer or inoperable advanced cancer. * Patients are under standard palliative care (SPC) at hospice setting and have no further curative options available. * Patients with BFI fatigue score 4 during screening. * Patients have a life expectancy of at least 3 months as determined by the investigator. * Patient must be willing and able to complete quality of life questionnaires. Exclusion Criteria: * Female patients are pregnant or breast-feeding. * Patients with uncontrolled systemic disease such as active infection, severe heart disease, uncontrollable hypertension or diabetes mellitus. * Patients take central nervous system stimulators such as Methylphenidate within 30 days before screening. * Patients have enrolled or have not yet completed other investigational drug trials within 30 days before screening. * Patients with Karnofsky Performance Scores less than 30 % at time of screening * Patients who are diagnosed as dying status
References
Publications (0)
Data not yet available
No reference posted for this study.